1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

BackgroundDurvalumab is the standard-of-care as consolidation therapy after chemo-radiation (ChRT) in stage III non-resecable non-small cell lung cancer (NSCLC). Its activity across NSCLC patients (pts) with genomic alterations (GA) poorly characterized. We aimed to assess durvalumab outcomes context of oncogenic addition.MethodsRetrospective study pts treated ChRT between Apr/15 and Oct/20 at 25 centres from Europe United States. Clinical biological data were collected; driver GA (dGA) included EGFR/all-BRAF/all-KRAS mutations (m) ALK/ROS1 rearrangements (r). Radiological response was assessed according RECIST v1.1 or investigator’s criteria. evaluated progression-free survival (PFS) overall (OS) based on dGA.ResultsTable: 1172MOPFS mo. (95%CI)OS rate 18 % (95%CI)Overall dGA14.9 (8.1-NR)93.4 (84.7-100)KRASm KRASm G12CNR (14.9-NR)NR (11.3-NR)89.7 (76.8-100)87.5 (67.3-100)EGFRm EGFRmdel19/ex219 (5.8-NR)8.1 (5.8-NR)100 (NR-NR)100 (NR-NR)BRAFm BRAFmV600E3.9 (3.9-NR)8.4 (3.9-NR)100 (NR-NR)ALKr7.8 (7.7-NR)100 (NR-NR) Open table a new tab Within dGA pts, neither OS nor PFS correlated PD-L1 expression, whereas positively associated smoking status: 19.2 (95%CI, 11.3-NR) vs. 5.8 3.9-NR) non-smokers (P=0.001).ConclusionsWe observed limited dGA, except for those harbouring KRASm. Larger studies are needed confirm these findings.Legal entity responsible studyThe authors.FundingHas not received any funding.DisclosureE. Auclin: Financial Interests, Institutional, Other: Mundipharma; Personal Sanofi Genzymes. R. Lopez Castro: Sponsor/Funding, Advisory role, lectures, other: Roche; Sponsor/Funding: Boehringer Ingelheim; Role, Lectures, Honoraria, Research: Bristol Myers Squibb; AstraZeneca; Novartis. J. Bosch Barrera: Research Grant: Pfizer; MSD; BMS; Novartis; Pierre Fabre; Ingelheim. S. Pilotto: Funding, Lectures: Merck Serono; Invited Speaker: Lilly; Amgen; Takeda. M. Tagliamento: Takeda; Writing Engagements: Amgen. E. Nadal: Funding: Board: D. Signorelli: Role: Sharp & Dohme; Squibb. B. Besse: AbbVie; BioGene; Blueprint Medicines; Celgene; Cristal Therapeutics; Daiichi Sankyo; Eli GSK; Ignyta; Ipsen; Inivata; Janssen; KGaA; Nektar; Onxeo; OSE Immunotherapeutics; PharmaMar; Roche-Genentech; Sanofi; Servier; Spectrum Pharmaceuticals; Tiziana Pharma; Tolero Pharmaceuticals. Planchard: Research, Merck; prIME Oncology; Honoraria: Peer CME; Principal Investigator: MedImmune; Sanofi-Aventis; Taiho Novocure. L. Mezquita: Tecnofarma; Chugai. All other authors have declared no conflicts interest. addition. Durvalumab MethodsRetrospective dGA. Retrospective ResultsTable: (P=0.001). ConclusionsWe findings.